Jim Plante is an investor and world-class technology leader who has generated hundreds of millions of dollars for portfolio companies. His work has helped the companies reach dominant positions in their industries regarding both value and offering best-of-breed offerings.
After earning a degree in Electrical Engineering from Southern Illinois University, Jim Plante spent over 25 years working as a successful technology entrepreneur and investor, with a focus in biotechnology and technology industries.
Mr. Plante played an integral part in the acquisition of Beltronics when he was 30 years old. Beltronics is well-known as the primary provider of high-performance millimeter wave radar safety systems across the globe, having produced and distributed more than 40 million units. As the president of Beltronics, Jim Plante helped the company launch an innovative new product line that put the company back in the green within 12 months. After the astounding turnaround, the company sold for more than a 1,200 percent return for investors.
Jim Plante also worked as the co-founder and CEO of E-Band Communications, launching the first multigigabit capacity 7080 GHz band communications links for mobile wireless infrastructure and fiber optic replacement in the industry. This product that Mr. Plante helped launch achieved 1 global market share drive and raised investors’ share value by more than 8,000 percent.
After that venture, he founded SmartDrive Systems in 2004 and served as the company’s CEO. The company is responsible for an innovative SAAS commercial vehicle safety program, which uses an integrated audio, video, GPS and sensor-based platform that monitors drivers and vehicles in real-time. Under the leadership of Jim Plante, the company expanded its workforce to over 400 employees and improved investors’ share value by more than 12,000 percent.
Jim Plante’s hard work as the founder and CEO (2008 – September 2017) of Pathway Genomics, in addition to his work as chairman of the company’s Board of Directors, resulted in the development of the state-of-the-art advanced genetic testing that continues to advance innovation to this day.
Mr. Plante was initially motivated to begin this company more than 30 years ago, when he discovered that his father had a genetic disorder known as polycystic kidney disease. Testing for this disease was not common then, and the condition that was afflicting Plante’s father was not found in time to delay kidney failure. When Jim Plante learned that he also had polycystic kidney disease and would need a kidney transplant, the news instilled powerful motivation in him to help others gain access to affordable genetic testing. He vowed to work toward ensuring that people could get tested for genetic diseases and disorders that might also get passed on to children.
The actions taken by Jim Plante and his team at Pathway Genomics have made actionable genetic information more accessible globally. The company’s advancements benefit individuals’ wellness and health by preventing disease and helping doctors develop personalized treatment plans.
Pathway Genomics thrived under Jim Plante’s leadership, during which the company established a CLIA and CAP accredited laboratory, offering the widest range of genetic tests in the industry. Using Pathway diagnostics, a patient’s genomes are examined to detect inherited genetic risk for heart disease, obesity, cancer and diabetes, and to gain insight into how a patient could react to a variety of commonly prescribed medications.
Mr. Plante is the founder of a 501(c)(3) nonprofit organization, known as the Foundation for Kidney Transplant Research. He also holds over fifty technology and biotechnical patents. To add to his achievements, the US Secretary of Commerce appointed Jim Plante as a member of the International Trade Advisory Committee.
To this day, Jim Plante works diligently to continue pushing for innovation in the healthcare industry through Thynk Capital and Pathway Genomics. Through these companies and as a private investor in healthcare, biotech and technology companies, he has increased his portfolio’s value by more than 2,000 percent.
Jim is currently the founder and CEO of Klotho Therapeutics, focusing on treatments for kidney diseases and the major diseases of again.